As of 2025-07-18, the EV/EBITDA ratio of Heron Therapeutics Inc (HRTX) is -71.05. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HRTX's latest enterprise value is 435.60 mil USD. HRTX's TTM EBITDA according to its financial statements is -6.13 mil USD. Dividing these 2 quantities gives us the above HRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.9x - 13.9x | 13.3x |
| Forward P/E multiples | 12.9x - 16.9x | 14.6x |
| Fair Price | (1.37) - (1.41) | (1.41) |
| Upside | -168.6% - -170.6% | -170.7% |
| Date | EV/EBITDA |
| 2025-07-17 | -71.05 |
| 2025-07-16 | -71.55 |
| 2025-07-15 | -72.04 |
| 2025-07-14 | -74.04 |
| 2025-07-11 | -75.53 |
| 2025-07-10 | -76.52 |
| 2025-07-09 | -76.77 |
| 2025-07-08 | -76.03 |
| 2025-07-07 | -74.78 |
| 2025-07-03 | -76.03 |
| 2025-07-02 | -74.78 |
| 2025-07-01 | -75.28 |
| 2025-06-30 | -72.79 |
| 2025-06-27 | -74.53 |
| 2025-06-26 | -75.03 |
| 2025-06-25 | -74.78 |
| 2025-06-24 | -74.78 |
| 2025-06-23 | -73.79 |
| 2025-06-20 | -71.05 |
| 2025-06-18 | -71.05 |
| 2025-06-17 | -69.81 |
| 2025-06-16 | -71.80 |
| 2025-06-13 | -69.31 |
| 2025-06-12 | -71.30 |
| 2025-06-11 | -72.54 |
| 2025-06-10 | -74.04 |
| 2025-06-09 | -74.04 |
| 2025-06-06 | -73.54 |
| 2025-06-05 | -71.05 |
| 2025-06-04 | -72.04 |
| 2025-06-03 | -71.05 |
| 2025-06-02 | -69.31 |
| 2025-05-30 | -68.06 |
| 2025-05-29 | -68.81 |
| 2025-05-28 | -66.82 |
| 2025-05-27 | -68.31 |
| 2025-05-23 | -67.32 |
| 2025-05-22 | -67.81 |
| 2025-05-21 | -68.06 |
| 2025-05-20 | -69.06 |
| 2025-05-19 | -69.06 |
| 2025-05-16 | -70.30 |
| 2025-05-15 | -67.81 |
| 2025-05-14 | -64.08 |
| 2025-05-13 | -67.07 |
| 2025-05-12 | -72.29 |
| 2025-05-09 | -73.79 |
| 2025-05-08 | -75.28 |
| 2025-05-07 | -77.52 |
| 2025-05-06 | -81.50 |